BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38755673)

  • 1. Clinical and economic burden of organ damage among patients with systemic lupus erythematosus in a real-world setting in Germany.
    Schultze M; Garal-Pantaler E; Pignot M; Levy RA; Carnarius H; Schneider M; Gairy K
    BMC Rheumatol; 2024 May; 8(1):18. PubMed ID: 38755673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An evaluation of costs associated with overall organ damage in patients with systemic lupus erythematosus in the United States.
    Bell CF; Ajmera MR; Meyers J
    Lupus; 2022 Feb; 31(2):202-211. PubMed ID: 35060407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world medication use and economic outcomes in incident systemic lupus erythematosus patients in the United States.
    Kariburyo F; Xie L; Sah J; Li N; Lofland JH
    J Med Econ; 2020 Jan; 23(1):1-9. PubMed ID: 31589081
    [No Abstract]   [Full Text] [Related]  

  • 4. Association of the Systemic Lupus International Collaborating Clinics Frailty Index and Damage Accrual in Longstanding Systemic Lupus Erythematosus.
    Lima K; Legge A; Hanly JG; Lee J; Song J; Chung A; Ramsey-Goldman R
    Arthritis Care Res (Hoboken); 2023 Mar; 75(3):578-584. PubMed ID: 34590445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of early versus late systemic lupus erythematosus diagnosis on clinical and economic outcomes.
    Oglesby A; Korves C; Laliberté F; Dennis G; Rao S; Suthoff ED; Wei R; Duh MS
    Appl Health Econ Health Policy; 2014 Apr; 12(2):179-90. PubMed ID: 24573911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Burden of Systemic Lupus Erythematosus in Germany: Incidence, Prevalence, and Healthcare Resource Utilization.
    Schwarting A; Friedel H; Garal-Pantaler E; Pignot M; Wang X; Nab H; Desta B; Hammond ER
    Rheumatol Ther; 2021 Mar; 8(1):375-393. PubMed ID: 33544369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Healthcare Resource Use and Costs Associated with Organ Damage in Newly Diagnosed Adults with Systemic Lupus Erythematosus in the UK.
    Stirnadel-Farrant HA; Golam SM; Naisbett-Groet B; Gibson D; Langham J; Langham S; Samnaliev M
    Rheumatol Ther; 2023 Oct; 10(5):1183-1197. PubMed ID: 37400683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disease and economic burden increase with systemic lupus erythematosus severity 1 year before and after diagnosis: a real-world cohort study, United States, 2004-2015.
    Jiang M; Near AM; Desta B; Wang X; Hammond ER
    Lupus Sci Med; 2021 Sep; 8(1):. PubMed ID: 34521733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Charlson Comorbidity Index Is Related to Organ Damage in Systemic Lupus Erythematosus: Data from KORean lupus Network (KORNET) Registry.
    Kim SK; Choe JY; Lee SS
    J Rheumatol; 2017 Apr; 44(4):452-458. PubMed ID: 28298561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Impact of Systemic Lupus Erythematosus Flares on Clinical and Economic Outcomes: The CHAMOMILE Claims Database Study in Germany.
    Ding B; Pignot M; Garal-Pantaler E; Villinger B; Schefzyk S; Desta B; Stirnadel-Farrant HA; Schwarting A
    Rheumatol Ther; 2024 Apr; 11(2):285-299. PubMed ID: 38252212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Classification of Systemic Lupus Erythematosus: Systemic Lupus International Collaborating Clinics Versus American College of Rheumatology Criteria. A Comparative Study of 2,055 Patients From a Real-Life, International Systemic Lupus Erythematosus Cohort.
    Inês L; Silva C; Galindo M; López-Longo FJ; Terroso G; Romão VC; Rúa-Figueroa I; Santos MJ; Pego-Reigosa JM; Nero P; Cerqueira M; Duarte C; Miranda LC; Bernardes M; Gonçalves MJ; Mouriño-Rodriguez C; Araújo F; Raposo A; Barcelos A; Couto M; Abreu P; Otón-Sanchez T; Macieira C; Ramos F; Branco JC; Silva JA; Canhão H; Calvo-Alén J; ;
    Arthritis Care Res (Hoboken); 2015 Aug; 67(8):1180-5. PubMed ID: 25581417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mortality and disease related comorbidities in systemic lupus erythematosus: Data from an Egyptian cohort.
    A Mohammed RH; Lotfy Fayed H; Ibrahim Emara N
    Lupus; 2022 Apr; 31(5):628-636. PubMed ID: 35306918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Healthcare Resource Utilization and Associated Costs in Patients With Systemic Lupus Erythematosus Diagnosed With Lupus Nephritis.
    Bell CF; Wu B; Huang SP; Rubin B; Averell CM; Chastek B; Hulbert EM; Von Feldt J
    Cureus; 2023 Apr; 15(4):e37839. PubMed ID: 37214060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Burden of Immunosuppressant-Treated Lupus Nephritis: A German Claims Database Analysis.
    Garal-Pantaler E; Schultze M; Georgiou ME; Pignot M; Gairy K; Hunnicutt JN
    Rheumatol Ther; 2024 Feb; 11(1):113-127. PubMed ID: 38001304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Healthcare resource utilization and costs in patients with a newly confirmed diagnosis of lupus nephritis in the United States over a 5-year follow-up period.
    Bell CF; Wu B; Huang SP; Rubin B; Averell CM; Chastek B; Hulbert EM
    BMC Health Serv Res; 2024 May; 24(1):691. PubMed ID: 38822336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Healthcare Costs and Utilization for Patients With Systemic Lupus Erythematosus in China: A National Claims Database Study.
    He X; Lloyd E; Cooper S; Li L; Chauhan D; Juliao P; Quasny H; Bao C
    Value Health Reg Issues; 2023 Sep; 37():88-96. PubMed ID: 37379801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early damage as measured by SLICC/ACR damage index is a predictor of hospitalization in systemic lupus erythematosus (SLE).
    Raman L; Yahya F; Ng CM; Sockalingam S; Ramasamy K; Ratnam R; Raja J
    Lupus; 2020 Dec; 29(14):1885-1891. PubMed ID: 33040647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cost of flares among patients with systemic lupus erythematosus with and without lupus nephritis in the United States.
    Bell CF; Huang SP; Cyhaniuk A; Averell CM
    Lupus; 2023 Feb; 32(2):301-309. PubMed ID: 36542670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic high-dose glucocorticoid therapy triggers the development of chronic organ damage and worsens disease outcome in systemic lupus erythematosus.
    Tarr T; Papp G; Nagy N; Cserép E; Zeher M
    Clin Rheumatol; 2017 Feb; 36(2):327-333. PubMed ID: 27889859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index.
    Legge A; Kirkland S; Rockwood K; Andreou P; Bae SC; Gordon C; Romero-Diaz J; Sanchez-Guerrero J; Wallace DJ; Bernatsky S; Clarke AE; Merrill JT; Ginzler EM; Fortin PR; Gladman DD; Urowitz MB; Bruce IN; Isenberg DA; Rahman A; Alarcón GS; Petri M; Khamashta MA; Dooley MA; Ramsey-Goldman R; Manzi S; Zoma AA; Aranow C; Mackay M; Ruiz-Irastorza G; Lim SS; Inanc M; van Vollenhoven RF; Jonsen A; Nived O; Ramos-Casals M; Kamen DL; Kalunian KC; Jacobsen S; Peschken CA; Askanase A; Hanly JG
    Arthritis Rheumatol; 2020 Apr; 72(4):658-666. PubMed ID: 31631584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.